HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multicenter, pilot-study to compare the efficacy and
safety of LDV/SOF fixed dose combination (FDC) in subjects with acute genotype 1 HCV
infection. A total of 20 subjects will be assigned to receive LDV/SOF FDC tablet (LDV 90
mg/SOF 400 mg/) once daily for 6 weeks.Patients will be followed up for 24 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
HepNet Study House, German Liverfoundation
Collaborators:
Gilead Sciences Hannover Clinical Trial Center GmbH Hannover Medical School
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir